(September 14, 2016 at 12:05 pm)Rhythm Wrote: GMO Biopharmaceuticals.
In addition to the public backlash against GE, there are costly and time consuming regulations in place for the approval of a GMO for human consumption. Not so for the raw biomass it takes to manufacture pharmaceutical products. There are hundreds of known species and thousands of known cultivars that are currently the basis of commercial medical production around the world. All any of these species needs is a novel trait which can be supported by a chemical back-end and specialized production equipment.
"pubic backlash", rather.